Associate Professor Anna Hearps
Co-Program Director, Disease Elimination; Head, Infection, Inflammation and Innate Immunity
Working groups
Reports and other work
-
Covid-19 Global Trends and Analysis - Volume 2: SARS-CoV-2 viral load dynamics and infectivity.
Covid-19 Global Trends and Analysis - Volume 2: SARS-CoV-2 viral load dynamics and infectivity.
Burnet publications
View 62 moreAfucosylated broadly neutralising antibodies targeting HIV envelope elicit enhanced NK cell-mediated cytotoxicity against HIV-infected CD4+ T cell and macrophage targets
Journal of Leukocyte Biology
Olaf G. Wilhelm et al
Lactic acid produced by optimal vaginal Lactobacillus species potently inactivates HIV-1 by several mechanisms including promoting inhibition of virion-associated reverse transcriptase activity and viral RNA degradation
Research Square (Research Square)
Muriel Aldunate et al
Adaptive NK Cells Rapidly Expand during Acute HIV Infection and Persist Despite Early Initiation of Antiretroviral Therapy
The Journal of Immunology
Anna C. Hearps et al
Current projects
View 10 moreEVE-M®: enhancing the vaginal environment and microbiome
The vaginal microbiome is a key determinant of a women’s sexual and reproductive health. There is an unmet need for effective non-antibiotic-based strategies to target bacterial vaginosis and its adverse sequelae.
Testing treatments for long COVID, a collaborative clinical trial
HEAL APT: Harnessing effective approaches for long COVID therapies through an adaptive platform trial.
Immunotherapy-based approaches to cure HIV
The objectives of this project include identifying the relevant NK subset which is the most potent killer of HIV-infected cells and developing anti-HIV antibodies with enhanced function.
